Mounjaro®
Starting from £179.99/mo
Start journey Learn moreNo — Wegovy is not licensed or clinically recommended as a once-monthly injection for maintenance. The medicine is designed as a once-weekly subcutaneous injection at every stage of treatment, including the maintenance phase, and moving to monthly dosing would not maintain the steady blood levels the medicine relies on. If you are wondering whether your dosing schedule can be reduced once you reach your target weight, the short answer is that once-weekly remains the standard, and any change to that schedule is a decision for your prescriber, not something to try unilaterally. These are prescription-only medicines assessed and prescribed on an individual clinical basis.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
It is a fair question, and our prescribers hear versions of it regularly. Once you have been on Wegovy for several months and your weight has stabilised, the obvious thought is: do I still need to inject every single week? The injections are not painful for most people, but they are still a weekly commitment, and once the dramatic early weight loss slows to a plateau, it can feel like the medicine is doing less. That feeling is partly right, in the sense that maintenance is a different phase from the rapid-loss phase. But it does not mean the medicine is doing nothing.
Semaglutide works by sustaining a certain concentration in your body that suppresses appetite and slows gastric emptying. That concentration needs topping up every seven days. Stretch the interval to four weeks and levels drop substantially, appetite returns, and the biological conditions that led to weight gain reassert themselves. This is not a willpower issue; it is pharmacokinetics. The NHS's semaglutide guidance is clear that the once-weekly frequency is not a starting recommendation that loosens over time, it is the schedule for the duration of treatment.
The confusion sometimes arises because people conflate frequency with dose. Those are two different levers. Frequency (how often you inject) stays at once weekly. Dose (how many milligrams) is what your prescriber may adjust during maintenance, and that is a genuinely nuanced clinical conversation worth having.
After titrating from 0.25mg through 0.5mg, 1.0mg and 1.7mg over roughly four months, most people reach the standard maintenance dose of 2.4mg weekly. The recently approved 7.2mg dose (cleared by the MHRA in April 2026 for adults with a BMI of 30 or above) extends that ceiling further for people who respond well and tolerate it. You can read more about the full range in our overview of Wegovy doses.
Maintenance, in clinical terms, means the dose and frequency at which you sustain the weight loss achieved during titration. It does not automatically mean the highest dose; some people find that, as our page on the Wegovy maintenance dose explains, a lower amount can be enough to sustain progress over the long term. What it always means, under the licensed schedule, is once weekly. NICE's recommendation under TA875 specifies semaglutide for up to two years within a specialist weight management pathway, which is another reason to plan the maintenance phase carefully with your prescriber rather than adjusting it ad hoc.
One practical consideration: if you are picking up your pen on a Thursday and the next feels far away, it is worth noting that consistency of day matters more than the specific day you choose. Many people anchor their injection to a fixed weekly routine (the same morning, the same spot in the fridge) and that rhythm tends to reduce missed doses. Missing a dose entirely is different from reducing frequency, and the patient information leaflet and your prescriber's guidance cover what to do in that situation.
Not for Wegovy specifically, and not in a way that has led to any licensed recommendation. Some research into GLP-1 medicines more broadly has looked at whether extended intervals might be viable once a stable weight is achieved, but no such schedule has been approved by the MHRA or recommended by NICE for semaglutide. The question of what happens when you stop or reduce Wegovy is explored separately, there is reasonable evidence that weight tends to return when treatment stops, which is one reason why the two-year licensed maximum under NHS guidance prompts careful planning.
If you are thinking about the maintenance phase from a cost angle (wondering whether stretching doses could reduce spending) our page on what to expect on the Wegovy maintenance dose covers what the evidence says about that phase more fully. The short version: maintenance dosing is still active treatment, not a wind-down.
People sometimes ask about taking Wegovy every other week during maintenance as a halfway measure, again, this is not a licensed or clinically endorsed schedule, and the answer follows the same logic as monthly dosing: semaglutide levels fall too far in the extended gap.
Talk to your prescriber. That is not a deflection, it is genuinely where the useful conversation lives. If weekly injections feel burdensome, or if you are reaching a point where you wonder whether your dose needs reviewing, our guidance on the Wegovy maintenance dose at 1mg is a useful starting point for understanding how lower doses are used in practice before you raise it with your clinician. Your prescriber can look at whether a lower maintenance dose suits you, discuss the timeline and what stopping treatment would likely mean, and help you weigh that against your longer-term health goals.
At nume, every repeat order is reviewed by a GPhC-registered Independent Prescriber before it is dispensed, a real clinician reads your update, not a queue of automated checks. That ongoing relationship is exactly the right place to raise a question like this. If you are exploring whether Wegovy is the right treatment for you, or whether a different approach makes more sense, you can find out more on our Wegovy overview page or browse our treatment options more broadly. When you are ready to speak to one of our prescribers, checking your eligibility takes a few minutes and costs nothing.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.